The country’s top pharmaceutical companies are under pressure to keep their pipelines filled with promising new drugs, which means they will continue tapping start-up companies for breakthrough ideas.
But while the big drug companies might be in an acquisitive mood, they are making young companies work harder than they did in the past to get acquired, structuring deals in such a way that they continue to hold the cards even while shelling out big money for new innovations, a new report says.
